IPCA Laboratories share news, announcements and annual reports
NSE: IPCALABBSE: 524494Pharmaceuticals & BiotechnologyMid Cap
IPCA Laboratories Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1994 on BSE, Feb 1995 on NSE
Last close ₹1,927.80up ₹1.60 (0.08%)BSE ₹1,927.70
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,926.20.
30 Oct: open ₹1,945.20, high ₹1,964.90, low ₹1,921.40
52-week range of traded prices to 30 Oct 2026
₹1,268.00Low, 31 Oct 2025₹2,038.00High, 18 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹48,909 Cr229th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 37.34
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.07
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.31%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 17.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.07
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,53,52767.6% delivered
IPCA Laboratories shareholding disclosures
56 filed, newest first. Page 2 of 2.
Nov 2008
11 Nov · Disclosure
Ipca Laboratories Ltd. has informed the Exchange that the Compensation Committee of the Board of Directors in their meeting held on November 11, 2008 have granted 57,000 (Fifty Seven Thousand Only) options under Ipca Laboratories Ltd. - Employees Stock Option Scheme - 2006 (ESOS) to selected Employees of the Company. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Nov · Disclosure
Ipca Laboratories Ltd. has submitted to the Exchange disclosure in Form D in respect of equity shares of the Company allotted to Directors / Officers of the Company under Ipca Laboratories Limited - Employee Stock Option Scheme 2006 (ESOS), pursuant to Regulation 13(6) of the SEBI (Prohibition of Insider Trading) Regulation, 1992. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2008
11 Jul · Disclosure
Ipca Laboratories Ltd. has informed the Exchange that Company have received a disclosure pursuant to Regulation 13(3) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992 in Form C from HDFC Mutual Fund, Mumbai giving the details of acquisition of 2% or more shares of the Company as on July 07, 2008. Further the Company has submitted a copy of Regulation 7(3) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 in response to above disclosure made by HDFC Mutual Fund. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2007
28 Nov · Disclosure
Ipca Laboratories Ltd. has submitted to the Exchange a copy of the disclosure in respect of equity shares of the Company allotted to Directors/ employees under Ipca Laboratories Limited Employment Stock Option Scheme 2006(ESOS), Pursuant to Regulation 13(6) of the SEBI (Prohibition of Insider Trading) Regulation, 1992. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2007
31 Oct · Disclosure
Ipca Laboratories Ltd. has informed the Exchange vide its letter dated October 29, 2007 that : "The Compensation Committee of the Board of Directors in their meeting held on 29th October, 2007 have granted 1,10,000 (One Lac Ten Thousand Only) options under Ipca Laboratories Ltd - Employee Stock Option Scheme - 2006 (ESOS) to selected Employees of the Company and its subsidiary. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Oct · Disclosure
Premchand Godha, for and on behalf of himself, Kaygee Investments Pvt. Ltd. & Exon Laboratories Pvt. Ltd. has informed the Exchange that he alongwith Kaygee Investments Pvt. Ltd. & Exon Laboratories Pvt. Ltd. propose to acquire 15,22,402 Equity Shares representing 6.09% of the total paid up equity Share capital of Ipca Laboratories Ltd. from the following transferor: Chandurkar Investments Pvt. Ltd. The mode of proposed acquisition is by way of Inter-se Transfer and the date of proposed acquisition is between October 12, 2007 to October 17, 2007. The proposed acquisition price per share is between Rs.650/- to Rs.710/-. The shareholding of Premchand Godha, Kaygee Investments Pvt. Ltd. & Exon Laboratories Pvt. Ltd. after the proposed acquisition would be 75,01,842 shares aggregating to 30.01% of the shares/voting rights of Ipca Laboratories Ltd. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.